Abzena (ABZA); signs strategic agreements with Telix for $5.9m

Published on 02-07-2018 07:25:20
Author Sparks Team

ABZA signs GMP manufacturing and bioconjugation agreements with Telix Pharmaceuticals (Telix) for a combined value of $5.9m. These projects are estimated to be largely completed within a 15-month period.

Under the terms of the agreements, ABZA will progress two PSMA-targeting monoclonal antibodies for targeted treatment of metastatic prostate cancer. On completion of cell line development by ABZA, the research cell banks for both antibodies will be transferred to ABZA’s San Diego facility for further process development, generation of master cell banks, and scale-up for manufacturing up to 500L. The company will also develop a bioconjugation process for one of the antibodies. The process will be performed in Cambridge, UK, before transferring it to ABZA’s GMP manufacturing facility in San Diego for batch production.

Share this with friends and colleagues